The Royal's Institute of Mental Health Research Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial
2018
NCT03674671
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

The Royal's Institute of Mental Health Research

Active Ingredients

Drugs in Phase 3 Trials (1)

ketamine (ketalar) (1 trial)

Drugs in Phase 1 Trials (1)

bupivacaine (Exparel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bipolar Disorder (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2